Valuation: Verastem, Inc.

Market Cap 596M 514M 483M 440M 827M 56.98B 838M 5.66B 2.22B 28.55B 2.24B 2.19B 94.95B P/E 2026 *
-4.1x
P/E 2027 * -5.65x
Enterprise Value 638M 551M 517M 470M 885M 60.98B 897M 6.06B 2.37B 30.55B 2.39B 2.34B 102B EV / Sales 2026 *
5.48x
EV / Sales 2027 * 3.29x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day+8.13%
1 week+2.95%
Current month+20.52%
1 month+15.92%
3 months+64.08%
6 months+19.28%
Current year-9.46%
1 week 6.44
Extreme 6.44
7.18
1 month 5.54
Extreme 5.54
7.18
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+8.21%+2.95%-12.30%-28.60% 596M
+4.80%+7.80%+70.64%+114.21% 70.07B
+17.12%+11.50%+49.15%+87.30% 52.87B
+3.07%-5.45%+0.11%+479.90% 27.02B
+2.26%+0.65%+49.19%+10.30% 23.61B
-1.38%-1.40%-18.70%-19.18% 23.38B
-6.00%+13.71%+244.39%+443.26% 19.43B
+3.80%+5.62%+39.57%-15.26% 18.75B
+0.38%-3.15%+20.39%+589.77% 15.85B
+2.64%-1.06%+38.77%+149.52% 12.7B
Average +3.49%-2.11%+48.12%+181.12% 26.43B
Weighted average by Cap. +5.10%-1.15%+55.14%+170.04%

Financials

2026 *2027 *
Net sales 116M 101M 94.31M 85.9M 162M 11.13B 164M 1.11B 433M 5.58B 437M 428M 18.55B 181M 156M 147M 134M 251M 17.32B 255M 1.72B 674M 8.68B 680M 665M 28.86B
Net income -166M -143M -134M -122M -230M -15.86B -233M -1.57B -617M -7.95B -623M -609M -26.43B -157M -136M -127M -116M -218M -15.02B -221M -1.49B -584M -7.52B -590M -577M -25.03B
Net Debt 41.9M 36.17M 33.94M 30.91M 58.12M 4.01B 58.92M 398M 156M 2.01B 157M 154M 6.68B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
18/08/26 US$7.000 +6.38% 1,128,640
14/08/26 US$6.580 -1.35% 1,280,177
13/08/26 US$6.670 -4.03% 1,856,897
12/08/26 US$6.950 -1.42% 1,263,817
11/08/26 US$7.050 +3.83% 2,087,689
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.580USD
Average target price
14.75USD
Spread / Average Target
+124.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock